Loading company…
Cambridge-area biotech developing next-generation cell and gene therapies for cancer, founded in 2015 in Massachusetts.
Based in Massachusetts and founded in 2015, Obsidian Therapeutics develops next-generation cell and gene therapies for cancer. Its cytoDRiVE platform controls protein activity using an FDA-approved small molecule, and its cytoTIL15 tumor-infiltrating lymphocyte program is moving toward first clinical data in metastatic melanoma. The company raised USD 160.5 million in a Series C led by Wellington Management in April 2024, valuing it at USD 503.80 million post-money.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in